<DOC>
	<DOCNO>NCT00295191</DOCNO>
	<brief_summary>This study aim investigate effect high flux dialyser use ultra pure dialysate utilization cardiovascular disease evaluate cardiovascular morbidity mortality , progression carotid artery intima-media thickness coronary artery calcification , inflammatory state , lipid level , nutritional status , erythropoietin requirement hemodialysis patient population . It hypothesize intervention project may diminish cardiovascular disease hemodialysis patient .</brief_summary>
	<brief_title>Multiple Interventions Related Dialysis Procedures Order Reduce Cardiovascular Morbidity Mortality HD Patients ( EGESTUDY )</brief_title>
	<detailed_description>This propose prospective , randomize , control study aim investigate effect high flux dialyser use ultra pure dialysate utilization cardiovascular disease evaluate cardiovascular morbidity mortality , progression carotid artery intima-media thickness coronary artery calcification , inflammatory state , lipid level , nutritional status , erythropoietin requirement hemodialysis patient population . It hypothesize intervention project may diminish cardiovascular disease hemodialysis patient . Their beneficial effect may directly represent significantly reduce cardiovascular morbidity mortality . The propose additional investigation , possible decrease progression coronary artery calcification carotid artery intima-media thickness , help u understand mechanism expect reduction serve surrogate marker atherosclerosis , case benefit intervention proven statistical significance . Seven hundred four hemodialysis patient treat Ege University Hospital Dialysis Unit eight FMC Clinics enrol study ( 3-year follow-up ; percentage yearly expect end-point 10 % ; expect event-free survival rate control group three year 72.9 % , bilateral alpha risk equal 5 % ; 90 % power detect increase 15 % event-free survival end 3-year follow-up favor intervention group ) . Annual drop-out rate estimate % 15-20 . It design 2x2 factorial ; case , first , randomize high flux dialyser low flux dialyser arm ; , re-randomized ultra pure ( online-produced use Diasafe check endotoxin measurement ) standard dialysate arm . The study last three year ; intermediate analysis perform 18th month . Primary end-point composite cardiovascular mortality myocardial infarction , stroke , revascularization , unstable angina pectoris require hospitalization ( 18 ad 36th month ) . Secondary end-points overall mortality , progression coronary artery calcification , progression carotid artery intima-media thickness , change post-dialysis body weight upper mid-arm circumference , hematocrit relate rHu-EPO dos , change level albumin , transferrin , total cholesterol , triglyceride , HDL cholesterol , LDL cholesterol , high sensitive CRP , Î²-2 microglobulin . At 0-18-36 month , coronary artery calcification assess multi-slice CT carotid artery intima-media thickness B-mode ultrasonography . Lipids CRP measure every three month .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Dialysis Solutions</mesh_term>
	<criteria>Aged 18 80 year On maintenance bicarbonate hemodialysis schedule thrice weekly , least 12 hours/week Willingness participate study write informed consent . To schedule live donor renal transplantation To serious lifelimiting comorbid situation ; namely active malignancy , active infection , endstage cardiac , pulmonary , hepatic disease ; pregnancy lactating</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>end-stage renal disease</keyword>
	<keyword>hemodialysis</keyword>
	<keyword>cardiovascular morbidity mortality</keyword>
	<keyword>high flux dialyser</keyword>
	<keyword>ultrapure dialysate</keyword>
	<keyword>coronary vascular calcification</keyword>
	<keyword>carotid intima-media thickness</keyword>
	<keyword>atherosclerosis</keyword>
</DOC>